219735-84-9Relevant academic research and scientific papers
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin- 3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists
Dzierba, Carolyn D.,Sielecki, Thais M.,Arvanitis, Argyrios G.,Galka, Amy,Johnson, Tricia L.,Takvorian, Amy G.,Rafalski, Maria,Kasireddy-Polam, Padmaja,Vig, Shikha,Dasgupta, Bireshwar,Zhang, Ge,Molski, Thaddeus F.,Wong, Harvey,Zaczek, Robert C.,Lodge, Nicholas J.,Combs, Andrew P.,Gilligan, Paul J.,Trainor, George L.,Bronson, Joanne J.,MacOr, John E.
scheme or table, p. 4986 - 4989 (2012/08/28)
Pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones were evaluated as corticotropin-releasing factor-1 receptor antagonists. The synthesis, SAR studies and pharmacokinetic evaluation of these analogs are described herein.
IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
-
Page/Page column 16-17, (2009/04/24)
The present invention relates to imidazopyridine analogs, methods of making imidazopyridine analogs, compositions comprising an imidazopyridine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising
Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.
Arvanitis, Argyrios G,Rescinito, Joseph T,Arnold, Charles R,Wilde, Richard G,Cain, Gary A,Sun, Jung Hui,Yan, Jia-Sheng,Teleha, Christopher A,Fitzgerald, Lawrence W,McElroy, John,Zaczek, Robert,Hartig, Paul R,Grossman, Scott,Arneric, Stephen P,Gilligan, Paul J,Olson, Richard E,Robertson, David W
, p. 125 - 128 (2007/10/03)
A series of high affinity CRF receptor ligands with an imidazo[4,5-b]pyridine core is described. Individual analogues were synthesized and tested in a rat CRF receptor binding assay. The best compounds were further tested in the dog N-in-1 pharmacokinetic model to assess plasma levels at 1mg/kg (po) and in the rat situational anxiety model to assess anxiolytic efficacy at 3mg/kg (po). The structure-activity relationships for good receptor binding affinity are described herein.
Imidazopyridines for the treatment of neurological disorders
-
Example 38, (2010/01/31)
Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
